2023/02/01 22:00:00 | |
---|---|
Price | |
291.60 USD | |
Difference | 0.24% (0.70) |
ISIN | US09062X1037 |
Symbol | BIIB |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 38,130 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 281.27 USD (100) |
Ask (Ask size) | 292.09 USD (1,500) |
Open | 289.57 USD |
High | 293.23 USD |
Low | 286.13 USD |
Close (prev. day) | 290.90 USD |
VWAP | 290.390787 USD |
Volume (pcs) | 755,494 |
Trading volume | 219,298,197.15 |
Number of trades | 19,399 |
Last size | 116,029 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2023/01/30 |
![]() |
Global Equity Ratings |
![]() |
2023/01/09 |
![]() |
Global Equity Ratings |
![]() |
2022/12/19 |
![]() |
Global Equity Ratings |
![]() |
2022/11/28 |
![]() |
Global Equity Ratings |
![]() |
2022/11/18 |
![]() |
Global Equity Ratings |
![]() |
2023/02/01 22:00:00 | |
---|---|
Price | |
291.60 USD | |
Difference | 0.24% (0.70) |
ISIN | US09062X1037 |
Symbol | BIIB |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 38,130 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 281.27 USD (100) |
Ask (Ask size) | 292.09 USD (1,500) |
Open | 289.57 USD |
High | 293.23 USD |
Low | 286.13 USD |
Close (prev. day) | 290.90 USD |
VWAP | 290.390787 USD |
Volume (pcs) | 755,494 |
Trading volume | 219,298,197.15 |
Number of trades | 19,399 |
Last size | 116,029 |
6m | 1Y | 3Y | |
Perf (%) | +39.35% | +27.13% | +8.46% |
Perf (abs.) | +82.34 | +62.23 | +22.75 |
Beta | 1.06 | 0.91 | 0.84 |
Volatility | 54.87 | 45.38 | 50.14 |
Ø price 5 days | Ø volume 5 days (pcs.) | 290.09 USD (735,694) |
Ø price 30 days | Ø volume 30 days (pcs.) | 283.25 USD (1,045,862) |
Ø price 100 days | Ø volume 100 days (pcs.) | 272.31 USD (1,511,425) |
Ø price 250 days | Ø volume 250 days (pcs.) | 233.78 USD (1,222,145) |
YTD High | date | 295.90 USD (2023/01/27) |
YTD Low | date | 265.32 USD (2023/01/05) |
52 Weeks High | date | 311.88 USD (2022/11/30) |
52 Weeks Low | date | 187.16 USD (2022/05/09) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
BX Swiss | 2023/01/13 | 18:00 | 266.237 CHF | 0.01 | 1 |
Berlin | 2023/02/01 | 21:45 | 266.25 EUR | 0.00 | 18 |
Duesseldorf | 2023/02/01 | 21:01 | 263.80 EUR | 0.00 | 9 |
Frankfurt | 2023/02/01 | 16:09 | 266.05 EUR | 0.00 | 2 |
Hamburg | 2023/02/01 | 08:04 | 264.75 EUR | 0.00 | 1 |
Hanover | 2023/02/02 | 08:06 | 266.05 EUR | 0.00 | 1 |
London Stock Exchange | 2023/01/19 | 12:59 | 283.47 USD | 3.67 | 1 |
Munich | 2023/02/01 | 08:00 | 264.85 EUR | 0.00 | 1 |
Nasdaq | 2023/02/01 | 22:00 | 291.60 USD | 219.30 | 19,399 |
SIX Swiss Exchange | 2022/09/28 | 17:36 | 222.00 CHF | 0.00 | 1 |
Stuttgart | 2023/02/01 | 19:41 | 263.75 EUR | 0.00 | 6 |
Tradegate | 2023/02/02 | 08:00 | 266.75 EUR | 0.01 | 1 |
Vienna Stock Exchange | 2023/02/01 | 17:32 | 264.10 EUR | 0.00 | 2 |
Xetra | 2023/02/01 | 17:35 | 263.95 EUR | 0.02 | 4 |
BIOGEN INC. |
- - |
225 Binney Street - 02142 Cambridge |
Telefon: 1-617-679-2000 |
Fax: - |
E-mail: info@biogen.com |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. |
Stelios Papadopoulos | Chairman of Board of Directors |
Alexander Denner | Member of Board of Directors |
Eric Rowinsky | Member of Board of Directors |
Maria Freire | Member of Board of Directors |
Richard Mulligan | Member of Board of Directors |
Stephen Sherwin | Member of Board of Directors |
Caroline Dorsa | Member of Board of Directors |
Jesus Mantas | Member of Board of Directors |
William Hawkins | Member of Board of Directors |
William Jones | Member of Board of Directors |
Christopher Viehbacher | Chairman of Managing Board |
Alphonse Galdes | Member of Executive Committee |
Anabella Villalobos | Member of Executive Committee |
Ginger Gregory | Member of Executive Committee |
Jake Elkins | Member of Executive Committee |
Mahalakshmi Radhakrishnan | Member of Executive Committee |
Priya Singhal | Member of Executive Committee |
Rohin Mhatre | Member of Executive Committee |
Michael Dambach | Member of Executive Committee |
Michael Hencke | Member of Executive Committee |
Michael McDonnell | Member of Executive Committee |
Rachid Izzar | Member of Executive Committee |
Robert Kilo | Member of Executive Committee |
Robin Kramer | Member of Executive Committee |
Susan Alexander | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer